{"slideshow_credits": null, "snippet": "A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.", "abstract": "Valeant Pharmaceuticals International has outperformed its rivals in industry due in large part to executive J Michael Pearson's aggressive practice of buying up existing drugs and then raising prices on them significantly, but tactic has drawn ire of consumers and attention of regulators; focus of regulators has many in industry worried, as many companies employ similar tactic, though not to extreme Valeant does.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}, {"firstname": "Sabrina", "role": "reported", "lastname": "TAVERNISE", "rank": 2, "organization": ""}], "original": "By ANDREW POLLACK and SABRINA TAVERNISE"}, "web_url": "http://www.nytimes.com/2015/10/05/business/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers.html", "lead_paragraph": "A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.", "headline": {"main": "Valeant\u2019s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers", "print_headline": "A Drug Company&#8217;s Price Tactics Pinch Insurers and Consumers"}, "_id": "5610f8bd38f0d85cd9760cec", "word_count": "1668", "multimedia": [{"height": 126, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2015/10/02/business/02drugprices-web1/02drugprices-web1-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-10-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "2"}, {"name": "persons", "value": "Pearson, John Michael (1959- )", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}